Maia Biotechnology

Maia Biotechnology Earnings Yield

The Earnings Yield of Maia Biotechnology (MAIA) as of Nov 10, 2026 is -31.50 %. In the previous year, Earnings Yield was -32.71 % — a change of -3.69% (higher).

Earnings Yield

-31.50 %

YoY

-3.69%

Last updated:

Earnings Yield of Maia Biotechnology is 2025 -31.50 % . Earnings Yield of Maia Biotechnology was 2024 -32.71 % . It decreases by -3.69% higher compared to the previous year.

The Maia Biotechnology Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-9.13 USD
Jan 1, 2020
-9.33 USD
Jan 1, 2021
-17.59 USD
Jan 1, 2022
-22.18 USD
Jan 1, 2023
-27.81 USD
Jan 1, 2024
-32.71 USD
Jan 1, 2025
-31.50 USD
The Maia Biotechnology Earnings Yield history
YEAREarnings YieldYoY
-31.50 %-3.69%
-32.71 %+17.61%
-27.81 %+25.39%
-22.18 %+26.12%
-17.59 %+88.41%
-9.33 %+2.22%
-9.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Maia Biotechnology Stock analysis

What does Maia Biotechnology do? MAIA Biotechnology, Inc. generates revenue through the development and commercialization of oncology drug candidates, focusing on targeted immuno-oncology therapies for difficult-to-treat cancers. The company's pipeline includes THIO (6-thio-dG, 6-thio-2’-deoxyguanosine), a telomere-targeting agent in Phase II clinical development for Non-Small Cell Lung Cancer, and Libtayo for advanced non-small-cell lung cancer treatment. MAIA is advancing a second-generation program with five compounds designed to improve specificity towards cancer cells and increase anticancer activity. The firm targets pharmaceutical companies and healthcare providers seeking innovative cancer treatments. The company's primary products are THIO and Libtayo, with THIO being a potentially first-in-class small molecule. MAIA is developing these therapies to improve and extend the lives of cancer patients, focusing on non-small-cell lung cancer and other difficult-to-treat cancers. The firm's second-generation pipeline aims to discover new compounds with enhanced properties compared to existing therapies. MAIA's clinical-stage approach allows it to partner with pharmaceutical entities for development and commercialization. MAIA Biotechnology's revenue model relies on the progression of its clinical-stage therapies through development phases, with potential partnerships and licensing agreements for commercialization. The company's focus on telomere-targeting agents like THIO positions it in the oncology drug development market. MAIA's pipeline includes Phase II studies for THIO in Non-Small Cell Lung Cancer, indicating near-term potential for partnerships or sales. The firm targets healthcare providers and pharmaceutical companies as key segments for its therapies. Maia Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Maia Biotechnology stock

Earnings Yield of Maia Biotechnology is -31.50 % in 2025.

Earnings Yield of Maia Biotechnology changed from -32.71 % to -31.50 %, representing a -3.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Maia Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Maia Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Maia Biotechnology

All Key Metrics — Maia Biotechnology